Abstract

Liver cancer poses a significant health burden worldwide, with early detection crucial for improving patient outcomes. This abstract outlines the diagnostic modalities available for the detection of liver cancer, focusing on both blood tests and imaging techniques. Serum biomarkers such as alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA), and cancer antigen 125 (CA125) have shown promise in the diagnosis of intrahepatic cholangiocarcinoma. Additionally, imaging tests play a vital role in identifying liver lesions and evaluating disease progression. By integrating these diagnostic approaches, clinicians can achieve more accurate and timely diagnoses, leading to better management strategies and improved patient survival rates.